MKI67 and breast carcinoma: Breast cancer treatment is based on the receptor status of the tumor, specifically estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2), as well as proliferative markers such as Ki67.